aibio
Financings ·
Compass Pathways prices about $150 million offering of ADSs and warrants
Each ADS sells for $4.275 with a warrant to buy another at $5.796. Full cash exercise of the warrants could lift gross proceeds to about $353 million.
CMPS COMPASS Pathways Plc
COMPASS Pathways Plc (CMPS) news CMPS offering news
Latest COMPASS Pathways Plc news
We have not published a story on COMPASS Pathways Plc yet. When there is news, it will appear here.
COMPASS Pathways Plc annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $118.4 million | $119.0 million |
| Net income (loss) | -$287.9 million | -$155.1 million |
| Cash from operations | -$157.2 million | -$119.2 million |
| Cash and equivalents | $149.6 million | $165.1 million |
Questions about COMPASS Pathways Plc
Has COMPASS Pathways Plc raised money recently?
Our latest story on this, dated Jan 10, 2025: "Compass Pathways prices about $150 million offering of ADSs and warrants". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of COMPASS Pathways Plc?
COMPASS Pathways Plc trades under the ticker CMPS on NASDAQ.
Where is COMPASS Pathways Plc listed?
COMPASS Pathways Plc is listed on NASDAQ. Our directory also records these other listings: BMV:CMPS/N.
What is the SEC CIK of COMPASS Pathways Plc?
The SEC Central Index Key (CIK) for COMPASS Pathways Plc is 1816590. Its filings are on SEC EDGAR.
How many shares does COMPASS Pathways Plc have outstanding?
138,476,822 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-05.
Which country or territory is COMPASS Pathways Plc listed under?
Our directory records COMPASS Pathways Plc under United Kingdom.
What does COMPASS Pathways Plc do?
Our directory classifies COMPASS Pathways Plc as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of COMPASS Pathways Plc?
The ISIN recorded for COMPASS Pathways Plc is US20451W1018.
Does aibio.space cover COMPASS Pathways Plc?
aibio.space lists COMPASS Pathways Plc among 2,820 public biotech companies and publishes its news here as stories appear.
Where is COMPASS Pathways Plc incorporated?
SEC records list its state or country of incorporation as X0.
Is COMPASS Pathways Plc profitable?
COMPASS Pathways Plc reported a net loss of $287.9 million for the fiscal year ended Dec 31, 2025, and used $157.2 million of cash in operations, per its annual report to the SEC.
How much does COMPASS Pathways Plc spend on research and development?
$118.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does COMPASS Pathways Plc have?
$433.3 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest COMPASS Pathways Plc (CMPS) stock news?
Our latest story on COMPASS Pathways Plc, dated Jan 10, 2025: "Compass Pathways prices about $150 million offering of ADSs and warrants". Each ADS sells for $4.275 with a warrant to buy another at $5.796. Full cash exercise of the warrants could lift gross proceeds to about $353 million. Source.
How long will COMPASS Pathways Plc's cash last?
From our story of Jan 10, 2025: The company estimates that the net proceeds will fund its operating expenses and capital expenditure requirements at least through the planned 26-week data read-out for COMP006. Source.
Investor discussion: COMPASS Pathways Plc
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,5.02,9.01). Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
- Financings
Reported a financing. SEC Form 424B5. Source
Stock chart
SEC filings and registration
- SEC name
- COMPASS Pathways plc
- CIK
- 1816590
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- CMPS (Nasdaq)
- State or country of incorporation
- X0
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 3RD FLOOR, 1 ASHLEY ROAD, CHESIRE, United Kingdom, WA14 2DT
- Phone
- 1-716-676-6461
- Shares outstanding
- 138,476,822 as of 2026-07-30 (10-Q filed 2026-08-05)
- Former names
- Compass Rx Ltd.
Recent filings
Listing details
- Company
- COMPASS Pathways Plc
- Ticker
- CMPS
- Listing
- NASDAQ
- Country or territory
- United Kingdom
- Business scope
- Biotechnology
- ISIN
- US20451W1018
- Other listed symbols
- BMV:CMPS/N
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction